Royalty Pharma 

Royalty Pharma 

Yahoo Finance • 6 days ago

Royalty Pharma PLC (RPRX) (Q2 2026) Earnings Call Highlights: Strong Growth and Raised Guidance

This article first appeared on GuruFocus. Portfolio Receipts: Grew 6% in Q2 2026 to $773 million, ahead of expectations. Royalty Receipts: Grew 14% in Q2 2026, driven by strong performances from Tremfya, Voranigo, Emdeltra, and Evrysdi. T... Full story

Yahoo Finance • 7 days ago

Royalty Pharma Q2 26 Earnings Conference Call At 8:00 AM ET

(RTTNews) - Royalty Pharma plc (RPRX) will host a conference call at 8:00 AM ET on August 5, 2026, to discuss Q2 26 earnings results. To access the live webcast, log on to https://www.royaltypharma.com/investors/events/ The views and opi... Full story

Yahoo Finance • 7 days ago

Royalty Pharma reports second quarter 2026 results

Royalty Pharma plc Portfolio Receipts growth of 6% to $773 million; Royalty Receipts growth of 14% Net cash provided by operating activities of $728 million Raised full year 2026 guidance: Portfolio Receipts expected to be $3,400 million... Full story

Yahoo Finance • 21 days ago

Royalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from Neurimmune

Royalty Pharma plc NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a portion of Neurimmune's royalty interest in AstraZeneca's cliramitug for up to $425 million, including... Full story

Yahoo Finance • 25 days ago

Royalty Pharma declares third quarter 2026 dividend

NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2026 of $0.235 per Class A ordinary share. The dividend will be paid... Full story

Yahoo Finance • last month

Royalty Pharma, plc (RPRX) Rallied on Earnings Beat

Meridian Funds, managed by ArrowMark Partners, released its first-quarter 2026 investor letter for "Meridian Hedged Equity Fund". A copy of the letter can be downloaded here. The Fund invests in high-quality growth companies and mitigates... Full story

Yahoo Finance • 2 months ago

Royalty Pharma to present at the Goldman Sachs 47th Annual Global Healthcare Conference

NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026 at 4:00 p.m.... Full story

Yahoo Finance • 3 months ago

Why One Fund’s $4 Million Centerra Gold Exit Looks Like Profit-Taking Amid a 150% Rally

On May 8, 2026, CM Management reported selling its entire 200,000-share stake in Centerra Gold(NYSE:CGAU), an estimated $3.56 million trade based on quarterly average pricing. What happened According to a Securities and Exchange Commissi... Full story

Yahoo Finance • 3 months ago

This Fund Cashed Out of Preformed Line Products Amid a 150% Stock Surge

On May 8, 2026, CM Management disclosed in a U.S. Securities and Exchange Commission (SEC) filing that it sold its entire stake in Preformed Line Products(NASDAQ:PLPC), an estimated $6.39 million trade based on quarterly average pricing.... Full story

Yahoo Finance • 3 months ago

Royalty Pharma plc Q1 2026 Earnings Call Summary

Royalty Pharma plc Q1 2026 Earnings Call Summary - Moby Strategic Performance and Market Positioning Delivered 13% growth in recurring royalty receipts, driven by a diversified portfolio and the absorption of the Promacta loss of exclusi... Full story

Yahoo Finance • 3 months ago

Royalty Pharma reports Q1 results; raises FY26 outlook

* Royalty Pharma press release [https://seekingalpha.com/pr/20502630-royalty-pharma-reports-first-quarter-2026-results] (RPRX [https://seekingalpha.com/symbol/RPRX]): Q1 Revenue of $631M (+11.1% Y/Y) misses by $243.12M. * Portfolio Rec... Full story

Yahoo Finance • 3 months ago

Royalty Pharma reports first quarter 2026 results

Royalty Pharma plc Portfolio Receipts growth of 10% to $925 million; Royalty Receipts growth of 13% Net cash provided by operating activities of $718 million Raised full year 2026 guidance: Portfolio Receipts expected to be $3,325 million... Full story

Yahoo Finance • 4 months ago

Q4 Earnings Roundup: Merck (NYSE:MRK) And The Rest Of The Branded Pharmaceuticals Segment

Let’s dig into the relative performance of Merck (NYSE:MRK) and its peers as we unravel the now-completed Q4 branded pharmaceuticals earnings season. Looking ahead, the branded pharmaceutical industry is positioned for tailwinds from adva... Full story

Yahoo Finance • 4 months ago

3 Unpopular Stocks We’re Skeptical Of

Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating bus... Full story

Yahoo Finance • 4 months ago

Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific Innovation

NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the launch of the Royalty Pharma Translational Prize, which recognizes exceptional achievements in translational medicine. The Prize will hono... Full story

Yahoo Finance • 4 months ago

Why Royalty Pharma Plc (RPRX) is One of the Most Undervalued Biotech Stocks to Buy Right Now

Royalty Pharma Plc (NASDAQ:RPRX) is one of the most undervalued biotech stocks to buy right now. Royalty Pharma Plc (NASDAQ:RPRX) announced on April 17 that its board of directors approved the payment of a dividend for the second quarter o... Full story

Yahoo Finance • 4 months ago

Royalty Pharma to Announce First Quarter 2026 Financial Results on May 6, 2026

NEW YORK, April 15, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2026 financial results on Wednesday, May 6, 2026 before the U.S. financial markets open. The company wil... Full story

Yahoo Finance • 4 months ago

Royalty Pharma plc (RPRX) Proved Resilience in Q1 by Gaining 25.6%

Patient Capital Management, based in Baltimore, released its first-quarter 2026 investor letter for the “Patient Opportunity Equity Strategy,” available for download here. The strategy’s long-term value approach aims to build wealth over t... Full story

Yahoo Finance • 4 months ago

Royalty Pharma, Johnson & Johnson Strike $500M Autoimmune Drug Deal

Johnson & Johnson (NYSE:JNJ) is included among the 13 Best Diversified Dividend Stocks to Buy Right Now.Royalty Pharma, Johnson & Johnson Strike $500M Autoimmune Drug Deal On March 30, Reuters reported that Royalty Pharma entered into a $... Full story

Yahoo Finance • 4 months ago

Johnson & Johnson’s JNJ-4804 Deal Adds Weight To Immunology Story

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Johnson & Johnson (NYSE:JNJ) has entered a $500m R&D co funding agreement with Royalty Pharma to advance JNJ-4804, a first in clas... Full story